Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1 2Phase 1/2 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 1Hepatic Veno-Occlusive Disease 1Colorectal Neoplasms 1Chemical and Drug Induced Liver Injury 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × S-Adenosylmethionine × Clear all
NCT06258525 2026-05-06

SAMe in Prevention of Oxaliplatin-associated Liver Injury

Cedars-Sinai Medical Center

Phase 2 Not yet recruiting
30 enrolled
Classical hematologyGastrointestinal

Hepatic Veno-Occlusive Disease, Colorectal Neoplasms, Chemical and Drug Induced Liver Injury

NCT07495995 2026-03-31

SAMeMASLDc-02

Cedars-Sinai Medical Center

Phase 2 Not yet recruiting
94 enrolled

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡